Mirum Pharmaceuticals Inc
$ 96.40
-0.52%
15 Apr - close price
- Market Cap 5,847,102,000 USD
- Current Price $ 96.40
- High / Low $ 97.37 / 94.94
- Stock P/E N/A
- Book Value 6.06
- EPS -0.47
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.09 %
- 52 Week High 109.28
- 52 Week Low 38.22
About
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Analyst Target Price
$125.36
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-11 | 2025-11-04 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-04 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.12 | 0.05 | -0.12 | -0.3 | -0.49 | -0.2979 | -0.52 | -0.54 | -0.66 | -0.57 | -1.94 | -0.8 |
| Estimated EPS | -0.0486 | -0.15 | -0.33 | -0.48 | -0.2466 | -0.45 | -0.47 | -0.48 | -0.24 | -0.63 | -0.8 | -0.94 |
| Surprise | -0.0714 | 0.2 | 0.21 | 0.18 | -0.2434 | 0.1521 | -0.05 | -0.06 | -0.42 | 0.06 | -1.14 | 0.14 |
| Surprise Percentage | -146.9136% | 133.3333% | 63.6364% | 37.5% | -98.7024% | 33.8% | -10.6383% | -12.5% | -175% | 9.5238% | -142.5% | 14.8936% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MIRM
2026-04-13 21:09:07
Mirum Pharmaceuticals has announced inducement grants, made under Nasdaq Listing Rule 5635(C)(4). The grants are typically provided to new employees as an inducement to join the company. This action reflects standard compliance with Nasdaq's listing rules concerning equity compensation.
2026-04-13 20:09:07
Mirum Pharmaceuticals announced inducement awards granted to 12 new employees on April 10, 2026, consisting of non-qualified stock options and restricted stock units (RSUs). These awards, approved by the Compensation Committee, are material inducements for employment under Nasdaq Listing Rule 5635(c)(4) and include vesting schedules tied to continued service.
2026-04-11 09:56:00
The article analyzes Mirum Pharmaceuticals Inc. (MIRM) using AI models to determine its effect on rotational strategy timing. It highlights strong sentiment across all horizons, an excellent risk-reward short setup, and offers three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for different risk profiles. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for the stock.
2026-04-11 06:34:00
Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating for Mirum Pharmaceuticals (MIRM) and set a price target of $140.00. The company recently reported strong quarterly revenue growth and a reduced net loss. Other analysts from RBC Capital also issued a Buy rating, while TipRanks – OpenAI maintained a Hold rating.
2026-04-10 12:39:28
Cantor Fitzgerald has reiterated an Overweight stock rating for Mirum Pharmaceuticals (NASDAQ: MIRM) with a price target of $140. The firm projects significant revenue growth for Mirum's products, potentially reaching $1 billion annually if Livmarli's EXPAND study succeeds, and believes volixibat and brelovitug will contribute meaningfully to profitability. Despite analysts not anticipating profitability this year, the company is approaching profitability with existing products and expects positive data for brelovitug for HDV, with other firms also optimistic about Mirum's pipeline developments.
2026-04-08 20:40:29
Mirum Pharmaceuticals filed an amended 8-K report detailing the full financial specifics of its acquisition of Bluejay Therapeutics and a concurrent $268.5 million PIPE financing. The filing includes Bluejay's audited 2025 financials, showing $85.6 million in assets and a $101.7 million net loss, and pro forma results of the combined entities. This amendment provides transparency on the financial impact of the acquisition, including the expensing of acquired in-process R&D, and the funding structure of the deal.
